| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
|
Medicine details |
|
| Medicine name | rivaroxaban (Xarelto®) |
| Formulation | film-coated tablet |
| Reference number | 559 |
| Indication | Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/11/2011 |
| NICE guidance | |